Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now?

Is BMY a bully banal to buy? We came crossed a bullish thesis connected Bristol-Myers Squibb Company connected MaxDividends’s Substack by Serhio MaxDividends. In this article, we volition summarize the bulls’ thesis connected BMY. Bristol-Myers Squibb Company's stock was trading astatine $59.43 arsenic of  March 26th. BMY’s trailing and guardant P/E were 16.61 and 9.20 respectively according to Yahoo Finance.

Jirsak/Shutterstock.com

Bristol Myers Squibb (BMY) is simply a starring planetary biopharmaceutical institution with a diversified portfolio focused connected oncology, immunology, and cardiovascular diseases, making it a reliable dividend-paying banal for semipermanent investors. The institution has a 17-year streak of consecutive dividend increases, presently yielding 4.63% with an yearly payout of $2.52 per share, supported by beardown escaped currency travel and profitability.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

BMY’s established products, including Opdivo and Eliquis, make unchangeable revenues adjacent amid patent expirations, portion its maturation portfolio—featuring drugs like Reblozyl, Breyanzi, and late-stage candidates specified as milvexian and admilparant—offers important upside potential. In 2024, BMY reported $48.3 cardinal successful revenue, up 7% year-over-year, with non-GAAP EPS of $1.15, reflecting resilient operational performance. Strategic partnerships, including collaborations with BioNTech and AI-driven initiatives, further accelerate innovation and fortify the pipeline.

The institution balances standard with biotech-like technological drive, investing heavy successful R&D and readying implicit 10 caller merchandise launches by 2030. Institutional backing from Vanguard, BlackRock, and State Street underscores assurance successful BMY’s strategy and fiscal stability. While the concern faces generic contention and occasional setbacks, its diversified gross streams, robust pipeline, and committedness to technological innovation mitigate risks, providing a resilient instauration for sustained maturation and shareholder returns.

Analysts support a “Buy” consensus, with an mean 12-month terms people of $57.64, reflecting mean upside potential. For investors seeking a operation of dependable dividends, beardown fundamentals, and semipermanent maturation successful a globally recognized pharmaceutical leader, Bristol Myers Squibb presents a compelling accidental with constricted downside risk.

Previously, we covered a bullish thesis on Bristol-Myers Squibb Company (BMY) by Magnus Ofstad successful March 2025, which highlighted the company’s high-risk, high-reward maturation imaginable driven by its neuroscience drug Cobenfy and broader pipeline. BMY’s banal terms has appreciated by astir 0.72% since our coverage. Serhio MaxDividends shares a akin presumption but emphasizes BMY’s reliable dividend way record, diversified portfolio, and dependable semipermanent growth.